Contribute Try STAT+ Today

AKRON, Ohio — A ballot proposal to rein in drug costs was soundly defeated in Ohio Tuesday after an expensive ballot fight that drew tens of millions of dollars from the pharmaceutical industry.

The ballot proposal, known as the Drug Price Relief Act, was rejected by nearly 80 percent of voters in final results. It would have required that state agencies pay no more for medicine than the U.S. Department of Veterans Affairs, which gets a 24 percent discount off average manufacturers’ prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • It seems to me that perhaps the greatest driving force behind high prescription drug prices was left out of this entire conversation – the pharmacy benefit managers, or PBMs. Their unyielding, unconscionable demands for higher and higher rebates from drug manufacturers is what causes prices to continually rise for patients, plan sponsors, and our government. This is not to say manufacturers don’t share some of the blame, e.g. limited availability generics with egregious pricing, authorized generics which keep prices up, and new drugs which are re-introduced into the market as a combination of two very inexpensive generics cause prices to rise as well. BUT, the mantra of the PBM industry “if you want to play in my sandbox you have to pay” exists on a larger scale than ever before and that needs to be soundly nipped in the bud. I for one will continue to expose their egregious actions and name names. They know, but won’t admit it. Their time is coming…………………..

  • This indeed has been defeated twice , while it is true some large groups Ohio Hospital Association and OSMA supported it this report leaves out the many more groups who did not support this issue . Perhaps including the ballot wording would assist your readers in their evaluation of this “news” item . Thank you

Comments are closed.